FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Mass Builder Elite

Muscle Growthadvanced
29
Share
ペプチド

4

平均日用量mcg

3,957

レベル

advanced

追加

May 16, 2026

概要

The Mass Builder Elite is an advanced-tier, multi-pathway muscle growth protocol designed for experienced users seeking maximum hypertrophy through sustained growth hormone elevation, enhanced recovery, and mitochondrial energy optimization. This four-peptide stack creates overlapping GH secretion patterns while MOTS-c provides the metabolic substrate efficiency needed to convert elevated anabolism into actual tissue accrual. CJC-1295 at 2000mcg three times per week provides the foundation with sustained GH-releasing hormone activity that elevates baseline growth hormone and IGF-1 levels for days between injections. Ipamorelin at 300mcg twice daily layers sharp, clean GH pulses on top of this elevated baseline without triggering cortisol, prolactin, or excessive appetite stimulation. Sermorelin at 500mcg on a 5-days-on/2-days-off schedule adds a third GH-releasing pathway through direct anterior pituitary stimulation, with the cycling protocol preventing receptor desensitization. MOTS-c at 5000mcg three times per week enhances mitochondrial function, improves glucose uptake into muscle cells, and activates AMPK to optimize the energy metabolism required for intensive training and recovery. The layered approach to GH secretion in this stack produces superior results compared to any single secretagogue: CJC-1295 raises the floor, Ipamorelin creates acute peaks, and Sermorelin maintains pituitary sensitivity. MOTS-c ensures that the metabolic machinery can actually utilize the elevated anabolic signaling for productive muscle protein synthesis rather than fat storage. Administer CJC-1295 on non-consecutive evenings (e.g., Monday, Wednesday, Friday). Ipamorelin should be taken morning and evening on an empty stomach. Sermorelin is best administered before bed during active days, with weekends off. MOTS-c can be taken on training days, ideally pre-workout. This stack is suited for advanced trainees with at least 3-5 years of serious resistance training, established nutrition protocols exceeding 1g protein per pound of bodyweight, and previous peptide experience. The multiple GH pathways require monitoring for potential water retention and joint changes. Research supports the amplification effect of combining GHRH analogs with ghrelin mimetics, while MOTS-c studies demonstrate improved exercise capacity and metabolic efficiency. Run for 12-16 weeks with blood work at baseline, week 6, and conclusion. A 6-week break between cycles is recommended.

投与プロトコル

2,000 mcg

1回の投与あたり

300 mcg

1回の投与あたり

500 mcg

1回の投与あたり

5,000 mcg

1回の投与あたり

目標と証拠

証拠ランク:community

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。